Drug Trial Radar · NCT04382937
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
Last checked: Nov 20, 2026Latest source record: Jan 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Jan 12, 2016
Primary completion
Jul 15, 2020
Study completion Jul 15, 2020
Sponsor
- Lead sponsor
- PharmaEssentiaIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: To demonstrate non-inferiority in sustained virologic response (SVR, undetectable HCV RNA at Follow up week 12) between PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily for the treatment of chronic HCV genotype 2 infection
Conditions
- Chronic Hepatitis C Virus Infection
Interventions
P1101 + RibavirinDrug
P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
PEG-Intron + RibavirinDrug
PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects with undetectable serum HCV RNA at follow up week 12Time frame: Follow Week 12
Locations
39 sites in 3 countries. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, China
Gansu Wuwei Tumour Hospital
Gansu, China
The First Hospital of Lanzhou University
Gansu, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, China
Henan Provincial People's Hospital
Henan, China
Luoyang Central Hospital
Henan, China
The First Hospital of Jilin University
Jilin City, China
Peace Hospital Affiliated to Changzhi Medical College
Shanxi, China
The Sixth People's Hospital of Shenyang
Shenyang, China
Tangdu Hospital, Fourth Military Medical University
Xi'an, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Xijing Hospital, Fourth Military Medical University
Xi'an, China
Soonchunhyang University Seoul Hospital
Asan, South Korea
Pusan National University Hospital
Busan, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Inha University Medical Center
Incheon, South Korea
Hanyang University Seoul Hospital
Seoul, South Korea
Seoul Metropolitan Government - Seoul National University Boramae Medical Center
Seoul, South Korea
Yonsei University Gangnam Severance Hospital
Seoul, South Korea
Saint Vincent Catholic Hospital
Suwon, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Chang Gung Memorial Hospital, Chiayi Branch
Chiayi City, Taiwan
Chia-Yi Christian Hospital
Chiayi City, Taiwan
Dalin Tzu Chi Hospital
Chiayi City, Taiwan
St. Martin De Porres Hospital
Chiayi City, Taiwan
Hualien Tzu Chi Hospital
Hualien City, Taiwan
Chang Gung Memorial Hospital, Kaohsiung Branch
Kaohsiung City, Taiwan
E-Da Hospital
Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital, Keelung Branch
Keelung, Taiwan
Chang Gung Memorial Hospital, Linkou
New Taipei City, Taiwan
China Medical University Hospital
Taichung, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
Chi Mei Hospital, Liouying
Tainan, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taitung MacKay Memorial Hospital
Taitung, Taiwan
National Taiwan University Hospital Yun-Lin Branch
Yuanlin, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.